Inflammation and Notch signaling: A crosstalk with opposite effects on tumorigenesis

Cell Death and Disease

Volumn 7, Issue 12, 2016, Pages

  Fazio, Chiara ^a   Ricciardiello, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

CARCINOGENESIS; ENTERITIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MALIGNANT NEOPLASM; NONHUMAN; NOTCH SIGNALING; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 85015227110     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.408     Document Type: Review

References (81)

1. Hori K, Sen A, Artavanis-Tsakonas S Notch signaling at a glance. J Cell Sci 2013; 126: 2135–2140.
2. Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991; 67: 687–699.
3. Artavanis-Tsakonas S Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770–776.
4. Andersson ER, Sandberg R, Lendahl U Notch signaling: simplicity in design, versatility in function. Development 2011; 138: 3593–3612.
5. Allenspach EJ, Maillard I, Aster JC, Pear WS Notch signaling in cancer. Cancer Biol Ther 2002; 1: 466–476.
6. Grishina IB. Mini-review: Does Notch promote or suppress cancer? New findings and old controversies. Am J Clin Exp Urol 2015; 3: 24–27.
7. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883–899.
8. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867.
9. Andersen P, Uosaki H, Shenje LT, Kwon C. Non-canonical Notch signaling: emerging role and mechanism. Trends Cell Biol 2012; 22: 257–265.
10. Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 2012; 134: 495–510.
11. Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L et al. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget 2014; 5: 10393–10406.
12. Geisler F, Strazzabosco M. Emerging roles of Notch signaling in liver disease. Hepatology 2015; 61: 382–392.
13. Qiao L, Wong BCY. Role of Notch signaling in colorectal cancer. Carcinogenesis 2009; 30: 1979–1986.
14. Shinoda M, Shin-Ya M, Naito Y, Kishida T, Ito R, Suzuki N et al. Early-stage blocking of Notch signaling inhibits the depletion of goblet cells in dextran sodium sulfate-induced colitis in mice. J Gastroenterol 2010; 45: 608–617.
15. Okamoto R, Tsuchiya K, Nemoto Y, Akiyama J, Nakamura T, Kanai T et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 2009; 296: G23–G35.
16. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006; 7: 678–689.
17. Kopan R. Notch signaling. Cold Spring Harb Perspect Biol 2012; 4: a011213.
18. Ayaz F, Osborne BA. Non-canonical notch signaling in cancer and immunity. Front Oncol 2014; 4: 345.
19. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med 2006; 6: 905–918.
20. Espinosa L, Inglés-Esteve J, Robert-Moreno A, Bigas A. IkappaBalpha and p65 regulate the cytoplasmic shuttling of nuclear corepressors: cross-talk between Notch and NF-κB pathways. Mol Biol Cell 2003; 14: 491–502.
21. Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J. NF-κB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 2013; 4: 2299.
22. Zheng X, Linke S, Dias JM, Gradin K, Wallis TP, Hamilton BR et al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci 2008; 105: 3368–3373.
23. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008; 118: 3660–3670.
24. Zou J, Li P, Lu F, Liu N, Dai J, Ye J et al. Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol 2013; 6: 3.
25. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/ progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007; 25: 807–815.
26. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008; 105: 6392–6397.
27. Chen J, Imanaka N, Griffin JD. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. BR J Cancer 2010; 102: 351–360.
28. Zavadil J, Cermak L, Soto-Nieves N, Böttinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO 2004; 23: 1155–1165.
29. Fazio C, Piazzi G, Vitaglione P, Fogliano V, Munarini A, Prossomariti A et al. Inflammation increases NOTCH1 activity via MMP9 and is counteracted by Eicosapentaenoic Acid-free fatty acid in colon cancer cells. Sci Rep 2016; 6: 20670.
30. Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernández-Majada V, Grilli A et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 2009; 106: 6315–6320.
31. Liu Z-J, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ et al. Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB J 2006; 20: 1009–1011.
32. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 2008; 33: 1223–1229.
33. Dotto GP. Notch tumor suppressor function. Oncogene 2008; 27: 5115–5123.
34. Raafat A, Bargo S, Anver MR, Callahan R. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). Oncogene 2004; 23: 9401–9407.
35. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002; 8: 979–986.
36. Nickoloff BJ, Hendrix MJC, Pollock PM, Trent JM, Miele L, Qin J-Z. Notch and NOXA-related pathways in melanoma cells. J Investig Dermatol Symp Proc 2005; 10: 95–104.
37. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 2005; 115: 3166–3176.
38. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001; 61: 3200–3205.
39. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33: 416–421.
40. Thélu J, Rossio P, Favier B. Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol 2002; 2: 7.
41. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436–444.
42. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D et al. IL-6 R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest 2014; 124: 1853–1867.
43. Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 2012; 106: 1833–1841.
44. Jundt F, Pröbsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511–3515.
45. Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K et al. Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget 2016 (e-pub ahead of print).
46. Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA et al. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J Clin Invest 2011; 121: 4685–4699.
47. Liu M, Lee D-F, Chen C-T, Yen C-J, Li L-Y, Lee H-J et al. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell 2012; 45: 171–184.
48. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 117: 3988–4002.
49. Guo S, Gonzalez-Perez RR. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLOS One 2011; 6: e21467.
50. Sun Y, Zhu D, Wang G, Wang D, Zhou H, Liu X et al. Pro-Inflammatory Cytokine IL-1β Up-Regulates CXC Chemokine Receptor 4 via Notch and ERK Signaling Pathways in Tongue Squamous Cell Carcinoma. PLOS One 2015; 10: e0132677.
51. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol Life Sci [Internet] 2007; 64: 2746–2762.
52. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002; 16: 2252–2263.
53. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421: 639–643.
54. Nickoloff BJ, Qin J-Z, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ 2002; 9: 842–855.
55. Quillard T, Charreau B. Impact of notch signaling on inflammatory responses in cardiovascular disorders. Int J Mol Sci 2013; 14: 6863–6888.
56. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011; 2011: 721608.
57. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107: 2223–2233.
58. Quillard T, Devallière J, Coupel S, Charreau B. Inflammation dysregulates Notch signaling in endothelial cells: implication of Notch2 and Notch4 to endothelial dysfunction. Biochem Pharmacol 2010; 80: 2032–2041.
59. Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA et al. Interleukin-6 stimulates defective angiogenesis. Cancer Res 2015; 75: 3098–3107.
60. Miyamoto S, Rosenberg DW. Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci 2011; 102: 1938–1942.
61. Shroyer NF, Helmrath MA, Wang VY-C, Antalffy B, Henning SJ, Zoghbi HY. Intestine-specific ablation of mouse atonal homolog 1 (Math1) reveals a role in cellular homeostasis. Gastroenterology 2007; 132: 2478–2488.
62. Van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435: 959–963.
63. Kim H-A, Koo B-K, Cho J-H, Kim Y-Y, Seong J, Chang HJ et al. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. J Clin Investig 2012; 122: 3248–3259.
64. Piazzi G, D’Argenio G, Prossomariti A, Lembo V, Mazzone G, Candela M et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. Int J Cancer 2014; 135: 2004–2013.
65. Taniguchi K, Wu L-W, Grivennikov SI, de Jong PR, Lian I, Yu F-X et al. A gp130–Src–YAP module links inflammation to epithelial regeneration. Nature 2015; 519: 57–62.
66. Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res 2010; 70: 792–801.
67. Pope JL, Bhat AA, Sharma A, Ahmad R, Krishnan M, Washington MK et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut 2014; 63: 622–634.
68. Lin J-T, Wang J-Y, Chen M-K, Chen H-C, Chang T-H, Su B-W et al. Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Exp Cell Res 2013; 319: 2216–2229.
69. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32: 14–27.
70. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958–969.
71. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen T-E, Conklin LS et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009; 15: 341–352.
72. Outtz HH, Wu JK, Wang X, Kitajewski J. Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol 2010; 185: 4363–4373.
73. Xu H, Zhu J, Smith S, Foldi J, Zhao B, Chung AY et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol 2012; 13: 642–650.
74. Kueanjinda P, Roytrakul S, Palaga T. A novel role of Numb as a regulator of proinflammatory cytokine production in macrophages in response to toll-like receptor 4. Sci Rep 2015; 5: 12784.
75. Fukuda D, Aikawa E, Swirski FK, Novobrantseva TI, Kotelianski V, Gorgun CZ et al. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci USA 2012; 109: E1868–E1877.
76. Menke V, van Es JH, de Lau W, van den Born M, Kuipers EJ, Siersema PD et al. Conversion of metaplastic Barrett’s epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech 2010; 3: 104–110.
77. Van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005; 11: 496–502.
78. Kazanjian A, Noah T, Brown D, Burkart J, Shroyer NF. Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells. Gastroenterology 2010; 139: 918–928.
79. Moon CM, Kwon J-H, Kim JS, Oh S-H, Jin Lee K, Park JJ et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer. Int J Cancer 2014; 134: 519–529.
80. Byers T. Nutrition and cancer among American Indians and Alaska natives. Cancer 1996; 78: 1612–1616.
81. Fini L, Piazzi G, Ceccarelli C, Daoud Y, Belluzzi A, Munarini A et al. Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice. Clin Cancer Res 2010; 16: 5703–5711.